International Journal of Environmental Research and Public Health,
Journal Year:
2022,
Volume and Issue:
19(20), P. 13495 - 13495
Published: Oct. 18, 2022
Nonalcoholic
fatty
liver
disease
(NAFLD)
has
emerged
as
the
predominant
cause
of
chronic
injury;
however,
mechanisms
underlying
its
progression
have
not
been
fully
elucidated.
Pathophysiological
studies
stated
that
NAFLD
is
significantly
influenced
by
dietary
and
environmental
factors
could
participate
in
development
through
different
mechanisms.
Currently,
“plastic
pollution”
one
most
challenging
problems
worldwide
since
several
plastics
potential
toxic
or
endocrine
disputing
properties.
Specifically,
intake
microplastics
(MPs)
nanoplastics
(NPs)
water
diet
and/or
inhalation
from
suspended
particles
well
established,
these
found
human
samples.
Laboratory
animals
exposed
to
MPs
develop
inflammation,
immunological
responses,
disruptions,
alterations
lipid
energy
metabolism,
among
other
disorders.
additives
also
demonstrated
adverse
reactions.
There
evidence
their
are
“obesogens”
pathogenesis
modifying
gut
microbiota
composition
even
worsen
fibrosis.
Although
exposure
seems
clear,
relationship
with
requires
further
study,
prevention
be
a
possible
personalized
therapeutic
strategy.
Adequate
mitigation
strategies
worldwide,
reducing
pollution
levels
MPs,
reduce
risk
NAFLD.
Hepatology,
Journal Year:
2023,
Volume and Issue:
77(4), P. 1335 - 1347
Published: Jan. 3, 2023
Background
and
Aims:
NAFLD
is
a
leading
cause
of
liver-related
morbidity
mortality.
We
assessed
the
global
regional
prevalence,
incidence,
mortality
using
an
in-depth
meta-analytic
approach.
Approach
Results:
PubMed
Ovid
MEDLINE
were
searched
for
population-based
studies
from
1990
to
2019
survey
year
(last
published
2022)
per
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA).
Meta-analysis
was
conducted
random-effects
models.
Bias
risk
assessment
Joanna
Briggs
Institute.
Of
2585
reviewed,
92
(N=9,361,716)
met
eligibility
criteria.
Across
study
period
(1990–2019),
pooling
prevalence
estimates
ultrasound-defined
yielded
overall
30.05%
(95%
CI:
27.88%–32.32%)
30.69%
(28.4–33.09),
respectively.
Global
increased
by
+50.4%
25.26%
(21.59–29.33)
in
1990–2006
38.00%
(33.71–42.49)
2016–2019
(
p
<0.001);
+38.7%
25.16%
(19.46–31.87)
34.59%
(29.05–40.57)
=0.029).
The
highest
Latin
America
44.37%
(30.66%–59.00%),
then
Middle
East
North
Africa
(MENA)
(36.53%,
28.63%–45.22%),
South
Asia
(33.83%,
22.91%–46.79%),
South-East
(33.07%,
18.99%–51.03%),
(31.20%,
25.86%–37.08%),
(29.71%,
25.96%–33.76%),
Pacific
28.02%
(24.69%–31.60%),
Western
Europe
25.10%
(20.55%–30.28%).
Among
cohort
diagnosed
without
liver
biopsy,
pooled
rate
1000
PY
12.60
(6.68–23.67)
all-cause
mortality;
4.20
(1.34–7.05)
cardiac-specific
2.83
(0.78–4.88)
extrahepatic
cancer-specific
0.92
(0.00–2.21)
liver-specific
Conclusions:
30%
increasing
which
requires
urgent
comprehensive
strategies
raise
awareness
address
all
aspects
on
local,
regional,
levels.
Hepatology Communications,
Journal Year:
2023,
Volume and Issue:
7(10)
Published: Oct. 1, 2023
Background:
The
latest
meta-analyses
suggest
NAFLD
is
increasing
globally.
Its
limitations
may
preclude
accurate
estimates.
We
evaluated
the
global
burden
and
its’
trends
in
prevalence
liver–related
mortality
(LRM)
by
sex,
age,
region,
country
over
past
3
decades
using
data
from
Global
Burden
of
Disease
(GBD)
2019
study.
Methods:
Crude
age-standardized
NAFLD-LRM
rates
were
obtained
for
all-age
individuals
with
204
countries/territories
between
1990
2019.
Joinpoint
trend
analysis
assessed
time
trends.
Weighted
average
annual
percent
change
(APC)
period
1990–2019
2010–2019
reported.
Results:
All-age
(children
adults)
crude
increased:10.5%
(561
million)–16.0%
(1,236
million);
an
APC
increase:
+
1.47%
(95%
CI,
1.44%,
1.50%).
Among
adults
(+20
y),
increased
(1990:
17.6%,
2019:23.4%;
APC:
1.00%,
95%
CI:
0.97%,
1.02%).
In
groups,
rate
(per
100,000)
1.75%,
2019:
2.18%;
0.77%
0.70%,
0.84%).
By
analysis,
2010
to
2019,
worsening
LRM
observed
among
202
167
countries,
respectively.
there
1.24
billion
prevalent
cases
168,969
associated
deaths;
Asia
regions
accounted
57.2%
46.2%
NAFLD-LRM.
highest
was
Middle
East
North
Africa
(LRM
26.5%);
Central
Latin
America
(5.90
per
100,000).
Conclusions:
globally
groups—over
80%
countries
experienced
increase
These
have
important
policy
implications
affected
health.
Journal of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: July 28, 2023
Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
is
among
the
most
widespread
metabolic
globally,
and
its
associated
complications
including
insulin
resistance
diabetes
have
become
threatening
conditions
for
human
health.
Previous
studies
on
non-alcoholic
(NAFLD)
were
focused
liver's
lipid
metabolism.
However,
growing
evidence
suggests
that
mitochondrial
metabolism
involved
in
pathogenesis
of
NAFLD
to
varying
degrees
several
ways,
instance
cellular
division,
oxidative
stress,
autophagy,
quality
control.
Ultimately,
function
gradually
declines
as
a
result
dysfunction.
The
unable
transfer
excess
droplets
outside
liver.
Therefore,
how
regulate
hepatic
treat
has
focus
current
research.
This
review
provides
details
about
intrinsic
link
with
mechanisms
by
which
dysfunctions
contribute
progression.
Given
crucial
role
progression,
application
potential
multiple
improvement
modalities
(including
physical
exercise,
diabetic
medications,
small
molecule
agonists
targeting
Sirt3,
mitochondria-specific
antioxidants)
treatment
was
evaluated
hoping
provide
new
insights
into
treatment.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(2), P. 640 - 640
Published: Feb. 20, 2023
The
prevalence
of
non-alcoholic
fatty
liver
disease
(NAFLD)
has
soared
globally.
As
our
understanding
the
grows,
role
gut-liver
axis
(GLA)
in
NAFLD
pathophysiology
becomes
more
apparent.
Hence,
we
focused
mainly
on
small
intestinal
area
to
explore
GLA.
We
looked
at
how
multi-strain
probiotics
(MCP®
BCMC®
strains)
containing
six
different
Lactobacillus
and
Bifidobacterium
species
affected
gut
microbiota,
inflammatory
cytokines,
permeability
patients.
After
months
supplementation,
biochemical
blood
analysis
did
not
show
any
discernible
alterations
either
group.
Five
predominant
phyla
known
as
Actinobacteria,
Proteobacteria,
Firmicutes,
Bacteroidota
Fusobacteria
were
found
group
demonstrated
a
significant
cluster
formation
microbiota
composition
through
beta-diversity
(p
<
0.05).
This
significantly
reduced
three
unclassifiable
species:
unclassified_Proteobacteria,
unclassified_Streptococcus,
unclassified_Stenotrophomonas.
In
contrast,
placebo
showed
increase
Prevotella_melaninogenica
Rothia_mucilaginosa,
which
classified
pathogens.
Real-time
quantitative
PCR
mucosal
cytokines
revealed
decrease
IFN-γ
(-7.9
±
0.44,
p
0.0001)
TNF-α
(-0.96
0.25,
0.0033)
but
an
IL-6
(12.79
2.24,
0.0001).
terms
analysis,
group,
unfortunately,
positive
changes
ELISA
analysis.
Both
groups
exhibited
level
circulating
zonulin
(probiotics:
107.6
ng/mL
124.7,
=
0.005
vs.
placebo:
106.9
101.3,
0.0002)
zonula
occluden-1
(ZO-1)
-34.51
18.38,
0.0001
-33.34
16.62,
consumption
suggested
presence
well-balanced
composition.
Probiotic
supplementation
improves
dysbiosis
eventually
stabilised
expression
immune
function.
To
summarise,
research
probiotic
supplement
healthy
diet
lifestyle
is
required
address
its
underlying
causes.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(2), P. 397 - 397
Published: Feb. 8, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
widespread
contributor
to
chronic
globally.
A
recent
consensus
on
renaming
was
established,
and
metabolic
dysfunction-associated
steatotic
disease,
MASLD,
chosen
as
the
replacement
for
NAFLD.
The
disease’s
range
extends
from
less
severe
previously
known
non-alcoholic
(NAFL),
more
intense
steatohepatitis
(MASH),
(NASH),
characterized
by
inflammation
apoptosis.
This
research
project
endeavors
comprehensively
synthesize
most
studies
encompassing
wide
spectrum
of
topics
such
pathophysiology,
risk
factors,
dietary
influences,
lifestyle
management,
genetics,
epigenetics,
therapeutic
approaches,
prospective
trajectory
particularly
exploring
its
connection
with
organoids.
Journal of Agricultural and Food Chemistry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: April 12, 2024
Nonalcoholic
fatty
liver
disease
(NAFLD)
is
characterized
by
fat
accumulation
and
inflammation.
Epigallocatechin
gallate
(EGCG)
has
been
proven
to
be
effective
against
NAFLD,
but
its
hepatoprotective
mechanisms
based
on
the
"gut
microbiota-barrier-liver
axis"
are
still
not
fully
understood.
Herein,
results
demonstrated
that
EGCG
effectively
ameliorated
NAFLD
phenotypes
metabolic
disorders
in
rats
fed
a
high-fat
diet
(HFD),
inhibited
intestinal
barrier
dysfunction
inflammation,
which
also
supported
experiment
of
Caco-2
cells.
Moreover,
could
restore
gut
microbiota
diversity
composition,
particularly
promoting
beneficial
microbes,
including
short-chain
acids
(SCFAs)
producers,
such
as
Lactobacillus,
suppressing
Gram-negative
bacteria,
Desulfovibrio.
The
microbial
modulation
raised
SCFA
levels,
decreased
lipopolysaccharide
TLR4/NF-κB
pathway,
strengthened
function
via
Nrf2
pathway
activation,
thereby
alleviating
steatosis
Spearman's
correlation
analysis
showed
24
key
OTUs,
negatively
or
positively
associated
with
disorders,
were
reshaped
EGCG.
Our
suggested
combinative
improvement
dysbiosis,
dysfunction,
inflammation
might
potential
therapeutic
target
for
NAFLD.
